Evidence map›Paper›PMID 24657960›Full record

ArticlePloS one2014

Immune activation markers in peripartum women in Botswana: association with feeding strategy and maternal morbidity.

Elizabeth S Russell, Terence Mohammed, Laura Smeaton, Baitshepi Jorowe, Iain J MacLeod, Risa M Hoffman, Judith S Currier, Sikhulile Moyo, Max Essex, Shahin Lockman

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 2 countries.

Elizabeth S RussellHarvard AIDS Initiative, Department of Immunology and Infectious Diseases, Harvard School of Public Health, Boston, Massachusetts, United States of America; Botswana-Harvard AIDS Institute, Gaborone, Botswana.
Terence MohammedBotswana-Harvard AIDS Institute, Gaborone, Botswana.
Laura SmeatonCenter for Biostatistics in AIDS Research, Department of Biostatistics, Harvard School of Public Health, Boston, Massachusetts, United States of America.
Baitshepi JoroweBotswana-Harvard AIDS Institute, Gaborone, Botswana.
Iain J MacLeodHarvard AIDS Initiative, Department of Immunology and Infectious Diseases, Harvard School of Public Health, Boston, Massachusetts, United States of America; Botswana-Harvard AIDS Institute, Gaborone, Botswana.
Risa M HoffmanDavid Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, United States of America.
Judith S CurrierDavid Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, United States of America.
Sikhulile MoyoBotswana-Harvard AIDS Institute, Gaborone, Botswana.
Max EssexHarvard AIDS Initiative, Department of Immunology and Infectious Diseases, Harvard School of Public Health, Boston, Massachusetts, United States of America; Botswana-Harvard AIDS Institute, Gaborone, Botswana.
Shahin LockmanHarvard AIDS Initiative, Department of Immunology and Infectious Diseases, Harvard School of Public Health, Boston, Massachusetts, United States of America; Botswana-Harvard AIDS Institute, Gaborone, Botswana; Department of Medicine, Division of Infectious Diseases, Brigham and Women's Hospital, Boston, Massachusetts, United States of America.
Botswana Harvard AIDS Institute Partnership · BWUniversity of California, Los Angeles · USCancer Research And Biostatistics · US

Funding

PREVENTION OF MILK-BORNE TRANSMISSION OF HIV IN BOTSWANAR01HD037793 · NICHD · HARVARD UNIVERSITY (SCH OF PUBLIC HLTH) · PI ESSEX, MYRON E · 2000 to 2004
$6.9M
Training in HIV Genomics, Treatment, and Cure Research in BotswanaD43TW009610 · FIC · THE BOTSWANA HARVARD HEALTH PARTNERSHIP · PI SHAHIN LOCKMAN, Joseph Moeketsi Makhema · 2013 to 2026
$4.4M
Maternal and Infant Health and HAART Outcomes in the Mashi PMTCT Study, BotswanaR01HD044391 · NICHD · HARVARD UNIVERSITY (SCH OF PUBLIC HLTH) · PI LOCKMAN, SHAHIN · 2003 to 2010
$1.9M
FIC NIH HHS D43 TW009610NICHD NIH HHS R01 HD037793NICHD NIH HHS R01 HD044391NICHD NIH HHS R01 HD37793NICHD NIH HHS R01 HD44391
6 · The paper itself

Abstract

Hormone levels shift the immune state in HIV-uninfected pregnant and breastfeeding women away from Th1 responses and toward regulation to permit fetal tolerance. Limited data exist on inflammation during pregnancy or postpartum in HIV-infected women, though certain inflammatory markers are associated with adverse health outcomes among HIV-infected persons. We measured hsCRP, D-dimer, IFN-γ, IL-6, IL-10 and TNF-α at 34 weeks gestation and six months postpartum in HIV-infected women from the Botswana Mashi PMTCT trial who were randomized to breastfeeding or formula-feeding. Differences in inflammatory markers between gestation and postpartum periods, and by randomized feeding method, were estimated using generalized estimating equations, adjusting for baseline plasma HIV-1 viral load, CD4 count, calendar time, and antiretroviral treatment status. Additionally, we studied the association between marker concentrations at six months postpartum and major adverse clinical events over the following 4.5 years, using case-cohort sampling and adjusted Cox proportional hazards models. In 86 breastfeeding and 75 formula-feeding women, hsCRP and D-dimer decreased significantly between 34 weeks gestation and six months postpartum, while IFN-γ increased. There was no significant association between inflammatory marker change and randomized feeding method after adjusting for multiple comparisons and removing outliers. In univariate analysis, TNF-α, D-dimer, and IFN-γ concentrations at six months postpartum were significant predictors of subsequent clinical events, and TNF-α remained significant in multivariate analysis (HR = 4.16, p = 0.001). In young HIV-infected women in Botswana inflammatory marker concentrations did not differ significantly between women who breast- vs. formula-fed. However, postpartum TNF-α level was predictive of subsequent adverse clinical event.

Indexed as

Breast FeedingAnti-Retroviral AgentsBotswanaCD4 Lymphocyte CountFemaleFibrin Fibrinogen Degradation ProductsHIV InfectionsHumansInfant FormulaInfant, NewbornInterferon-gammaInterleukin-10Interleukin-6Multivariate AnalysisPeripartum PeriodPostpartum PeriodAnti-Retroviral AgentsFibrin Fibrinogen Degradation Productsfibrin fragment DInterferon-gammaInterleukin-10Interleukin-6Tumor Necrosis Factor-alpha

Identifiers

PMID24657960
PMCPMC3962339
OpenAlexW2037691852

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.